Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 5/20 | 0.62 |
| ▸ | PRKCG | P05129 | 5/20 | 0.62 |
| ▸ | PRKCB | P05771 | 5/20 | 0.62 |
| ▸ | PRKCA | P17252 | 5/20 | 0.62 |
| ▸ | PRKCH | P24723 | 5/20 | 0.62 |
| ▸ | PRKCI | P41743 | 5/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.62 |
| ▸ | PRKACA | P17612 | 2/20 | 0.62 |
| ▸ | PRKACG | P22612 | 2/20 | 0.62 |
| ▸ | PRKACB | P22694 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78989 | 1.00 | PRKD3 (0.62) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3959789 | 0.98 | PRKD3 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3148480 | 0.92 | NPC1 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL31615194 | 0.92 | NPC1 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3908537 | 0.88 | PRKD3 (0.59) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL6417753 | 0.88 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL12424814 | 0.85 | KDR (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL2986726 | 0.85 | PRKD3 (0.53) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3257968 | 0.84 | PRKD3 (0.49) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL15758300 | 0.83 | PRKCB (0.64) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | 4M THERAPEUTICS INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250228821-A1 | N-DESMETHYL RUBOXISTAURIN AS A KINASE INHIBITOR | 4M THERAPEUTICS INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4504178-A1 | N-DESMETHYL RUBOXISTAURIN AS KINASE INHIBITOR | 4M THERAPEUTICS INC. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024220957-A1 | POLYMORPHS OF N-DESMETHYL RUBOXISTAURIN AND SALTS THEREOF | 4M THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-110551678-B | SC-beta cells, compositions and methods for producing the same | 哈佛学院校长同事会 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023192984-A1 | N-DESMETHYL RUBOXISTAURIN AS KINASE INHIBITOR | 4M THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230285357-A1 | COMPOSITIONS AND METHODS FOR TRANSDIFFERENTIATING CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | PRKD3 2027/4885PRKCG 1702/4885PRKCB 1249/4885 |
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | GSK3B, GSK3A, LRRK2 | PRKD3 30/4885PRKCG 117/4885PRKCB 41/4885 |
| US-20250228821-A1 | N-DESMETHYL RUBOXISTAURIN AS A KINASE INHIBITOR | GSK3B, GSK3A, GSKIP | PRKD3 47/4885PRKCG 824/4885PRKCB 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.